Articles related to Oncology, Surgical

“By comparing current standard-of-care treatments with a potential novel therapy in refractory mCRC, this review underscores existing gaps and highlights future research priorities while awaiting randomized data.” – Elisabetta Bengala, MD, Regina Elena National Cancer Institute, Rome, Italy

Disease recurrence in HR+/HER2– early BC (EBC) can occur over decades; however, the hazard of recurrence is highest during the first 2 years of adjuvant endocrine therapy, a period associated with endocrine resistance and early metastatic progression.

The primary end point was the area under the curve (AUC) of the daily worst bone pain score (assessed using the “worst pain” question from the Brief Pain Inventory, a 0 to 10 numerical rating scale [NRS]) for 5 consecutive days in the first chemotherapy cycle.

Referral rates for newly diagnosed gynecological malignancy occurred in only 14.6% of eligible patients despite attendance rates of 81.7% when referrals were made.

“When 60% of ‘not medically necessary’ denials are reversed…we’re seeing algorithmic denial for delay’s sake.” — Anthony J. Paravati, MD, Kettering Health

The ABCDE warning signs help spot melanoma early, so counsel your patients regarding Asymmetry, Border, Color, Diameter, and Evolving (the mole or spot changes in size, shape, or color. It may also start to bleed, itch, or crust).